The new and expanded distribution agreements are directly related to Rockwell Medical's revenue generation and profitability. The expected $1 million in annual revenues from these agreements is a positive development for the company, likely to be viewed favorably by investors. The alignment with the company's gross margin guidance for 2024 further underscores the strategic importance of these agreements, suggesting a positive short-term impact on RMTI's stock price.